Mizuho has increased its price target for DexCom (NASDAQ:DXCM) to $90.00, maintaining an “outperform” rating and suggesting a 38% upside. This follows DexCom’s strong Q4 performance, where it surpassed EPS and revenue estimates, reporting $0.68 EPS and $1.26 billion in revenue. Despite positive analyst sentiment, the stock faces near-term headwinds including trading below moving averages and a high P/E ratio.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
DexCom (NASDAQ:DXCM) Price Target Raised to $90.00
Mizuho has increased its price target for DexCom (NASDAQ:DXCM) to $90.00, maintaining an “outperform” rating and suggesting a 38% upside. This follows DexCom’s strong Q4 performance, where it surpassed EPS and revenue estimates, reporting $0.68 EPS and $1.26 billion in revenue. Despite positive analyst sentiment, the stock faces near-term headwinds including trading below moving averages and a high P/E ratio.